Bioinformatic analysis indicates that both VEGFA and FGF2 are potential targets for miR-205 (Figure 3a), and this has been confirmed for VEGFA in osteosarcoma24, thyroid cancer25 and breast cancer MDA-MB-231 cells.34 VEGFA and FGF2 promote therapy resistance in a number of cancers35, 36, 37, 38 and, reassuringly, we have confirmed their overexpression both at the mRNA and protein levels in both MCF-7/A02 and CALDOX cells (Figure 3b). Here, FGF2 is linked to breast cancer.